

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE I CLINICAL TRIAL AND
COMPLETION OF FIRST PATIENT ENROLLMENT FOR
RECOMBINANT POLIOMYELITIS VACCINE

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that Phase I clinical trial for the Recombinant Poliomyelitis Vaccine developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled. The Company has completed the clinical trial filing with Therapeutic Goods Administration, a division under the Department of Health and Aged Care of Australian Government. The Recombinant Poliomyelitis Vaccine has also received an approval from the Human Research Ethics Committee in Australia for clinical trial prior to the filing of the clinical trial protocol.

Based on the protein structure design and VLP assembly technology of the Company, the Recombinant Poliomyelitis Vaccine expects to contribute substantially to global polio control including post-eradication. The Recombinant Poliomyelitis Vaccine is a non-infectious polio VLP vaccine with good safety and immunogenicity profiles that does not rely on live virus in the manufacturing process. Unlike existing attenuated and inactivated polio vaccines, non-infectious polio VLP vaccines are recommended by the World Health Organization as one of the preferred vaccines for polio in the future.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, January 15, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.